Alzheimer's and Parkinson's Disease

Published by: Global Industry Analysts

Published: May. 1, 2008 - 530 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Product Segments

Anti-Alzheimer’s Disease Drugs

Cholinesterase Inhibitors

NMDARA

Anti-Parkinson’s Disease Drugs

Dopaminergic Agents (Levodopa/Carbidopa)

Dopamine Agonists

Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine

Amplifiers)

COMT Inhibitors

MAO-B Inhibitors

Dopamine Amplifiers

II. EXECUTIVE SUMMARY

1. Outlook

Current and Future Analysis

2. Neurodegenerative Diseases Market - A Brief Overview

Key Brands in NDD Market

Table 1: Leading Drugs in the Global Neurodegenerative Disease Market (2004): Percentage Breakdown by Sales Revenues for Razadyne, Aricept, Exelon, Namenda, Sifrol / Mirapex, Requip, Cabaser, Madopar, Siemet, Permax, and Others (includes corresponding Graph/Chart)

Factors Affecting Market

Major Growth Drivers

Major Growth Inhibitors

Market Trends

High Prevalence Rates Drive Market Growth

Rapid Growth of Ageing Population

Price Hikes and Government Caps

Combination Therapy Gaining Ground

Research & Development

Future Holds Promise

3. Alzheimer’s Market Overview

A Peek at Anti-AD Drug Market

Impact of Dementia

Epidemiology

Table 2: World Alzheimer’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), and Rest of World (includes corresponding Graph/Chart)

Table 3: Alzheimer’s Disease Prevalence in Top Seven Countries (US, Japan, Germany, France, UK, Italy, and Spain) for Years 2001 through 2010: Number of Patients (in ‘000) Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) (includes corresponding Graph/Chart)

Table 4: Alzheimer’s Disease Diagnosis in Top Seven Countries (2005): Percentage of Diagnosed Patients in the US, Japan, Germany, France, Italy, Spain, and the UK (includes corresponding Graph/Chart)

Patient Growth Drivers

Demographics Spell Opportunities

High Growth Rates for AD Drugs

The Impact of Aricept

Epic of NMDARA

Strengths

Weaknesses

Future Therapies

How Successful will the Late Stage Therapies be?

A Geographic Milieu

US

Europe

Japan

Alternative Drug Delivery Technologies Gaining Ground

Transdermal Patch

Domination of Acetyl Cholinesterase Inhibitors

Dramatic Changes in Market Lie Ahead

Advances in Next-Generation Treatments

Beta Amyloid Hypothesis

Growth Drivers

Ageing Baby Boomers Drive AD Market

Table 5: AD Frequency Rate (%) (includes corresponding Graph/Chart)

New Hypothesis Enables Effective Treatment

Unmet Medical Needs Drive Market Growth

Growth Inhibitors

Link with Other Aliments

Misdiagnosis

Patient Awareness

Medical Refunds

Competitive Landscape

Pharmaceutical Majors Rule the Market

Eisai/Pfizer

Novartis

Shire/Johnson & Johnson

Lundbeck/Forest

Ipsen and UCB

Table 6: Leading Brands in the Global Anti- Alzheimer’s Drug Market (2005): Percentage Breakdown by Sales Revenues for Aricept, Exelon, Razadyne, Axura, Ebixa, Namenda, and Others (includes corresponding Graph/Chart)

Year of Approval of AD Drugs in Leading Countries

Compounds in Pipeline

Outlook for AD Drugs Market

4. Parkinson’s Disease Market Overview

An Alluring Market

Prevalence

Table 7: World Parkinson’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, Rest of Europe), and Rest of World (includes corresponding Graph/Chart)

Current Treatments

New Medicines on the Horizon

New Findings

Product Launches Through 2009

Dominance of Dopamine Agonists

Revival Revels in Other Anti-PD Drugs Segment

COMT Inhibitors Growing Fastest

Key Market Drivers

Rising Awareness Magnifies Patient Base

Emergence of Dopamine Agonists as First Line Treatment Drives Market Growth

The Debut of Stalevo

Unmet Clinical Needs Show Mammoth Prospects

Key Market Inhibitors

Limitations of Existing Medicines Inhibit Market Growth

Under-Diagnosis Restrains Market Potential

Generic Competition from L-Dopa and Carbidopa Curbs Market Growth

Restricted Term of Dopamine Agonists Usage Delays Market Growth

5. Disease Overview

Alzheimer's Disease

Definition

The Cause

Finding AD

Prevention

Treatment

Parkinson’s Disease

Definition

Pathophysiology

Diagnosis

Prevalence

Treatment

Surgical Intervention

6. Drug Classification

Anti-Alzheimer’s’ Disease Drugs

NMDARA

Memantine

Cholinesterase Inhibitors (ChEIs)

Donepezil (Aricept)

Rivastigmine (Exelon)

Galantamine Hydrobromide (Razadyne)

Tacrine (Cognex)

Other Alternatives

Vitamin E

Estrogen Therapy

Anti-Inflammatory Drugs

NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

Antioxidants

Vaccine

Gingko Biloba

Pure Medical Nicotine

Anti-Parkinson’s Disease Drugs

Dopaminergic agents

Levodopa/Carbidopa

Dopamine Agonists

Pergolide/Permax

Bromocriptine/Parlodel

Ropinirole/Requip

Pramipexole/Mirapex

Cabergoline/Dostinex

Apomorphine/Apokyn

Other Dopamine Agonists

Other PD Drugs

COMT Inhibitors

Tolcapone (Tasmar)

Entacapone (Comtan)

MAO-B Inhibitors

Dopamine Amplifiers

Anticholinergics

7. Future Therapies

Alzheimer’s Disease

Key Pipeline Products

Phenserine

Ropern

Alzhemed

MEM 1003

Ampakine Compounds

Parkinson’s Disease

Key Pipeline Products

Adenosine A2a Antagonist

Spheramine®

Safinamide

O-1369

8. New Findings

Risedronate Minimizes Risk of Hip Fractures in PD Patients

Researchers Identify New Genes Responsible for AD

Researchers Establish a New Link Between Loneliness and AD

Researchers Try to Identify Early Stages of AD

SORL1 - The New Gene Found to be Responsible for AD

Scientists Conduct Research Work on CERE-120 Gene Therapy

Researchers Find New Snail Toxin for Nervous System Disorders

Researchers Study Anti-PD Properties of Nicotine

Researchers Establish New Link Between Pesticides and PD

Study Relates AD to the Quantity of Amyloid Protein

Researchers Establish Effectiveness of Gene Therapy on AD Patients

Scientists Use Electric Current to Treat PD Patients

Scientists Prove Earlier Assumptions Wrong

Scientists Discover 2 Distinct Types of MCIs

9. Recent Industry Activity

Eisai Acquires MGI Pharma

Eli Lilly Begins Phase III Clinical Trial of Alzheimer's Disease Treatment

Merz Licenses Anti-Alzheimer’s Drug Technology from TAU

Eisai Acquires Morphotek

Transition Therapeutics Acquires NeuroMedix

Evotec Teams Up with Boehringer Ingelheim

Siemens Signs Partnership Agreement with Wyeth

Digilab Receives Notice of Allowance for New Alzheimer's Biomarker

Pfizer Joins Forces with Genizon

Intellect Signs Licensing Agreement with IBL

Boehringer Ingelheim signs R&D agreement with Ablynx

Avicena Teams Up with NINDS for Phase III Trial of PD-02

Prana Begins Phase II clinical trial for PBT2

Idera Teams Up with Merck

Merck Signs R&D Agreement with Neuroptix

Neuro-Hitech Takes Over Q-RNA

Neurogen Inks Licensing Agreement with Wyeth

Acumen Revises License Agreement with Merck

Newron Begins 2nd Phase III clinical trial for Safinamide

Newron Inks Global Licensing Agreement with Serono

Pfizer Inks License Agreement with TransTech

CeNeS Renews R&D Agreement with Tripos

Athenagen Acquires Zapaq

Neuren Starts Pre-clinical Studies of Anti-PD Drug - NNZ-2591

Teva Receives Health Canada Clearance for Azilect

Valeant Introduces Zelapar Anti-PD Tablets in the US

Merck to Halt Further Development of Anti-PD Drug Called Sarizotan

Amarin Obtains Global Rights for New Apomorphine Formulation

FDA Clears Exelon for Parkinson's Disease

Neuropharma Receives German Clearance for Phase 1 Clinical Trials of NP031112

Pfizer Takes Over Rinat

TorreyPines Begins 2nd Phase-I clinical trial for NGX267

Kyowa Hakko Inks Licensing Agreement with Britannia

Schwarz Pharma Receives EMEA Clearance for Neupro

Evotec Inks Licensing Agreement with Roche

RheoGene Receives Funds from MJFF

Eisai Initiates Phase I clinical trial for E2012

Apokyn(R) Receives Approval in North America

FDA Approves Azilect

Voyager Completes Phase II Study for of Leuprolide Acetate

New Discovery for the Treatment of Alzheimer's Disease in Canada

Ortho-McNeil Launches Razadyne™ ER

Flurizan Enters Phase II Clinical Trials

Axonyx Releases Supplementary Results of Phase III Trial for Phenserine

Predix Pharmaceuticals Starts Phase Ib Trials of 5-HT4 Agonist

BrainStorm Pronounces Advantages of GDNF Producing Stem Cells in Parkinson's Animal

Models

Predix’s PRX-03140 Completes First Clinical Trial in Alzheimer's Disease

Galapagos and Senexis Expand Collaboration

Novartis Joins Forces with Ono to Develop and Market AD Transdermal Patch

Neurologix Posts Interim Results of Phase I Gene Therapy

GB Therapeutics Receives License for CHF1512

Alzhemed™ Begins Phase III Trials

Newron Commences Phase III Trial With Safinamide

Ceregene Bags FDA Approval for Gene Therapy Alzheimer's Study

Memantine Drug Receives Approval from FDA for Treatment of Alzheimer’s

FDA Grants Fast Track Designation

Ester Neurosciences Joins Forces with Pharmacopeia

10. Focus on Select Players

Boehringer Ingelheim (Germany)

Bristol-Myers Squibb Co. (USA)

Eisai Inc. (USA)

Eli Lilly and Company (USA)

Forest Pharmaceuticals (USA)

GlaxoSmithKline PLC (UK)

H. Lundbeck A/S (Denmark)

Merz Pharmaceuticals GMBH (Germany)

Novartis AG (Switzerland)

Ortho-McNeil Neurologics, Inc. (USA)

Pfizer Inc (US)

Roche (Switzerland)

Shire Pharmaceuticals Group PLC (UK)

Valeant Pharmaceuticals International (USA)

11. Global Market Perspective

Table 8: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 9: World Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 10: World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 11: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 12: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 13: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 14: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 15: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 16: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets for 2003, 2008 & 2012

Table 17: World Recent Past, Current & Future Market Analysis for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 18: World Long-term Projections for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 19: World 10-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 20: World Recent Past, Current & Future Market Analysis for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2002 through 2010 (includes corresponding Graph/Chart)

Table 21: World Long-term Projections for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 22: World 9-Year Perspective for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart)

Table 23: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 24: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 25: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 26: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 27: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 28: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 29: World Recent Past, Current & Future Market Analysis for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 30: World Long-term Projections for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 31: World 10-Year Perspective for Dopaminergic Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 32: World Recent Past, Current & Future Market Analysis for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 33: World Long-term Projections for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 34: World 10-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 35: World Recent Past, Current & Future Market Analysis for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 36: World Long-term Projections for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 37: World 10-Year Perspective for Other PD Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A. Market Analysis

Current & Future Analysis

AD Market Overview

Approval of Cholinesterase Inhibitors for MCI to Drive Market

Competitive Landscape

Table 38: Leading Therapeutics in the North American Alzheimer’s Disease Market (2005 & 2004): Percentage Breakdown by New Prescription for Aricept, Exelon, Namenda, and Razadyne (includes corresponding Graph/Chart)

Status of AD Drugs

New Products in Clinical Trails

Prevalence

Table 39: Alzheimer’s Disease Prevalence in the US for Years 2005 through 2010 (includes corresponding Graph/Chart)

PD Therapies Market

Levodopa/Carbidopa on Declining Spree

Competition

Table 40: Leading Brands in the US PD Therapeutics Market (2004-2006E): Percentage Breakdown by Prescription for Generic Amantadine, Generic Benzitropine, Generic Levodopa/Carbidopa, Comtan, Mirapex, Requip, Generic Selegiline, Sinemet/Sinemet CR, Rasagiline, and Others (includes corresponding Graph/Chart)

Patent Expiry Status

Patent Expiry Status of Parkinson’s Disease Drugs in the US

New Brands and Pipeline Analysis

PD Prevalence

New Findings

Strategic Corporate Developments

Key Players

B. Market Analytics

Table 41: US Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 42: US Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 43: US 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

A. Market Analysis

Current & Future Analysis

Prevalence

Strategic Corporate Developments

B. Market Analytics

Table 44: Canadian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 45: Canadian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 46: Canadian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

A. Market Analysis

Current & Future Analysis

Prevalence

Strategic Corporate Developments

B. Market Analytics

Table 47: Japanese Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 48: Japanese Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 49: Japanese 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

A. Market Analysis

Current & Future Analysis

Prevalence

Alzheimer’s Disease

Table 50: European Alzheimer’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart)

Parkinson’s Disease

Table 51: European Parkinson’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart)

Competitive Scenario

Table 52: Leading Brands in the European Alzheimer’s Disease Market (2005): Percentage Breakdown by New Prescription for Aricept, Ebixa/Auxura, Exelon, and Razadyne (includes corresponding Graph/Chart)

Strategic Corporate Developments

B. Market Analytics

Table 53: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 54: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 55: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 56: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 57: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for Germany, France, UK, Italy, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 58: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. Germany

A. Market Analysis

Current & Future Analysis

Prevalence

Strategic Corporate Developments

Key Players

B. Market Analytics

Table 59: German Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 60: German Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 61: German 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. France

A. Market Analysis

Current & Future Analysis

Prevalence

B. Market Analytics

Table 62: French Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 63: French Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 64: French 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. United Kingdom

A. Market Analysis

Current & Future Analysis

Prevalence

New Findings

Strategic Corporate Developments

Key Players

B. Market Analytics

Table 65: UK Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 66: UK Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 67: UK 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. Italy

A. Market Analysis

Current & Future Analysis

Prevalence

Strategic Corporate Developments

B. Market Analytics

Table 68: Italian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 69: Italian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugsby Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 70: Italian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Spain

A. Market Analysis

Current & Future Analysis

Prevalence

B. Market Analytics

Table 71: Spanish Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 72: Spanish Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 73: Spanish 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4f. Rest of Europe

A. Market Analysis

Current & Future Analysis

Prevalence

New Findings

Strategic Corporate Developments

Key Players

B. Market Analytics

Table 74: Rest of Europe Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 75: Rest of Europe Long-term Projections for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 76: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Rest of World

A. Market Analysis

Current & Future Analysis

Prevalence

Strategic Corporate Developments

B. Market Analytics

Table 77: Rest of World Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 78: Rest of World Long-term Projections for Anti-Alzheimer’s & Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 79: Rest of World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 87 (including Divisions/Subsidiaries - 105)

Region/Country Players

The United States 51

Canada 5

Japan 3

Europe 36

France 1

Germany 9

The United Kingdom 11

Italy 2

Spain 3

Rest of Europe 10

Asia-Pacific (Excluding Japan) 5

Middle East 5

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.